Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Doxorubicin vs TC in Adjuvant HR+/HER2- Early Breast Cancer
NCT05302336Phase 4Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 4 trial of pegylated liposomal doxorubicin in breast cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05302336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05302336.